EU High Court Clarifies Generics Question In J&J Case

Law360, New York (June 18, 2009, 12:00 AM EDT) -- Europe's highest court has ruled that drugmaker Generics UK Ltd. should not be permitted to market a generic version of Alzheimer's disease treatment Reminyl — a victory for Johnson & Johnson and Shire PLC that settles a key question over drug product exclusivity in the European Union.

Generics UK had asked the European Court of Justice, Europe's highest court, to review a UK regulator's refusal to grant marketing authorization to the company for a generic version of the Alzheimer's drug Reminyl.

Reminyl contains the active ingredient...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.